hsa-miR-27b-3p directly targets HSP90AA1 and Fzd7 in NSCLC, ROR1 in gastric cancer, and CBLB/GRB2 in breast cancer to suppresses cell proliferation, migration, invasion, and expression of MET [32, 33]. Here, MET is linked to breast carcinoma.